World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
161
Citations
136886
World Ranking
734
National Ranking
417

Robert J. Motzer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert J. Motzer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,134 publications — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert J. Motzer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert J. Motzer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 161 D-Index — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert J. Motzer is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on medicine, with significant contributions to biochemistry, genetics, and molecular biology.

The main areas of study encompass pulmonary and respiratory medicine, oncology, molecular biology, cancer research, and economics and econometrics as applied to medical research.

Specific topics addressed in their work include:

  • Renal cell carcinoma treatment
  • Cancer immunotherapy and biomarkers
  • Renal and related cancers
  • Cancer genomics and diagnostics
  • Economic and financial impacts of cancer
  • Bladder and urothelial cancer treatments
  • Pancreatic and hepatic oncology research

Frequent coauthors in their publications include Toni K. Choueiri, Martin H. Voss, Ritesh R. Kotecha, Chung-Han Lee, and A. Ari Hakimi.

They have published extensively in several venues, with the most notable being:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • The Journal of Urology
  • European Urology
  • The Oncologist

Among their recent papers are:

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma, 2021, New England Journal of Medicine
  • Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network

Other influential recent publications related to renal cell carcinoma and cancer treatment, although not authored by Robert J. Motzer but relevant in their field, include:

  • Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma, 2021, New England Journal of Medicine
  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial, 2020, ESMO Open

Best Publications

  • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George

  • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

    Gary Hudes;Michael Carducci;Piotr Tomczak;Janice Dutcher

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

    Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

  • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    Robert J Motzer;Bernard Escudier;Stéphane Oudard;Thomas E Hutson

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;M. Dror Michaelson;Bruce G. Redman;Gary R. Hudes

  • Renal-cell carcinoma.

    Robert J. Motzer;Neil H. Bander;David M. Nanus

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

  • Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;David Cella;James Reeves

  • Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma

    Robert J. Motzer;Madhu Mazumdar;Jennifer Bacik;William Berg

  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

    Brian I. Rini;Bernard Escudier;Piotr Tomczak;Andrey Kaprin

  • Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma

    Robert J. Motzer;Jennifer Bacik;Barbara A. Murphy;Paul Russo

  • Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Brian I. Rini;Brian I. Rini;Ronald M. Bukowski;Brendan D. Curti

  • Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

    Robert J. Motzer;Bernard Escudier;Stephane Oudard;Thomas E. Hutson

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

    Robert Motzer;Boris Alekseev;Sun Young Rha;Camillo Porta

  • Testicular Germ-Cell Cancer

    George J. Bosl;Robert J. Motzer

  • Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

    Toni K. Choueiri;Thomas Powles;Mauricio Burotto;Bernard Escudier

  • Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Toni K. Choueiri;Bernard Escudier;Thomas Powles;Paul N. Mainwaring

Frequent Co-Authors

Toni K. Choueiri
Toni K. Choueiri Harvard University
Dean F. Bajorin
Dean F. Bajorin Memorial Sloan Kettering Cancer Center
Bernard Escudier
Bernard Escudier Institut Gustave Roussy
George J. Bosl
George J. Bosl Memorial Sloan Kettering Cancer Center
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Paul Russo
Paul Russo Memorial Sloan Kettering Cancer Center
Thomas E. Hutson
Thomas E. Hutson Texas Oncology
Thomas Powles
Thomas Powles Queen Mary University of London
Victor E. Reuter
Victor E. Reuter Memorial Sloan Kettering Cancer Center
James J. Hsieh
James J. Hsieh Washington University in St. Louis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online degrees can open new doors within healthcare and adjacent fields. For aspiring nurses looking to advance their credentials efficiently, rn to np programs online offer a flexible route from registered nurse to nurse practitioner, often blending online coursework with required clinical hours.

Nutrition is another growing field for those interested in prevention and wellness. Accredited best online nutrition degree programs provide a solid foundation in nutritional science, helping graduates pursue roles as dietitians, wellness coaches, or public health educators.

For those drawn to healthcare leadership, online mha programs cahme accredited ensure quality education for future healthcare administrators. These degrees prepare students to manage hospitals, clinics, or healthcare systems with a focus on efficiency and patient care.

Registered nurses wanting to advance without in-person requirements can benefit from an rn to bsn without clinicals program. This pathway makes it easier to upgrade credentials while balancing work and other commitments.

Whether your passion is direct patient care, nutrition, or healthcare management, these online programs can support diverse career pathways in and around the field of medicine.

Best Scientists Citing Robert J. Motzer

Trending Scientists

Recently Published Articles